The AI That Won't Chat Just Raised $870M. Plus: A Calcium Pill's Trial | Tech Arcade Podcast

TypeSafe has raised $870 million at a $7.5 billion valuation for Jev, a model that returns a yes or no, a pick from a list or a score instead of text. We explain how that works, and why the speed and cost figures all come from the company and its lead investor. Then: BridgeBio's experimental pill encaleret for a rare calcium disorder, where 76% of patients hit the trial's main target against 4% on standard treatment, and what is still unproven.

Full story: https://www.techarcade.io/the-ai-that-only-answers-yes-no-or-a-number-just-raised-870-million/

Full story: https://www.techarcade.io/a-calcium-pill-just-beat-standard-care-76-to-4-and-switched-a-missing-hormone-back-on-in-9/

Sources

TypeSafe announcement: https://typesafe.ai/blog/series-ai

Andreessen Horowitz: https://a16z.com/announcement/investing-in-typesafe-ai/

Unite.AI: https://www.unite.ai/typesafe-ai-raises-870m-series-a-at-7-5b-valuation-to-ship-more-ai-models/

SiliconANGLE: https://siliconangle.com/?p=850033

Crypto Briefing: https://cryptobriefing.com/a16z-leads-typesafe-ai-series-a/

BridgeBio release, 11 October 2026: https://www.globenewswire.com/news-release/2026/10/11/3378507/0/en/encaleret-increased-bone-turnover-and-improved-participant-reported-symptoms-in-the-phase-3-calibrate-trial-in-adh1.html

BridgeBio release, 29 October 2025: https://www.globenewswire.com/news-release/2025/10/29/3176268/0/en/BridgeBio-Reports-Positive-Phase-3-Topline-Results-for-Encaleret-in-Patients-with-Autosomal-Dominant-Hypocalcemia-Type-1.html

Note: TypeSafe says a third of the Fortune 500 use Jev; Andreessen Horowitz says 25%. BridgeBio's 2026 release gives parathyroid hormone recovery on standard care as 0%; its 2025 release gave 7%.

This episode is news, not medical advice.

More at https://www.techarcade.io

#techarcade #technews #AI #startups #biotech